Literature DB >> 25036855

Predictors of severe self-reported disability in RA in a long-term follow-up study.

Karina Malm1, Stefan Bergman, Maria Andersson, Ann Bremander.   

Abstract

PURPOSE: Identify factors predictive for severe self-reported disability in patients with rheumatoid arthritis.
METHODS: Patients (n = 1910) were sent a questionnaire 5-18 years after disease onset. Outcomes were the Health Assessment Questionnaire (HAQ), Rheumatoid Arthritis Outcome Score (RAOS) and physical activity. The tertile of patients most affected by the disease were compared to those less affected. Proposed predictive factors were function, pain, general health, radiographic joint damage, swollen/tender joints and disease activity measures at baseline. Age, gender and disease duration were controlled for in logistic regression analyses.
RESULTS: Seventy-three percent (n = 1387) responded to the questionnaire, mean age 65 years (SD 15) and 70% were women. Worse scores in function, pain, general health and tender joints at baseline increased the risk of being in the most affected group, as measured by HAQ and RAOS 5-18 years after disease onset (p < 0.000).
CONCLUSION: High levels of pain and worse reports of function at disease onset were risk factors for being in the most disabled tertile of patients after 5-18 years. Pain and function proved to be predictors of the outcome while some measures of inflammation were not. It is important to recognize these patients who may be in need of multidisciplinary treatments already at disease onset. IMPLICATIONS FOR REHABILITATION: Health care providers should be aware of the subgroup of patients with more severe symptoms of pain and impaired function at disease onset since they have an increased risk of being in the most disabled tertile of rheumatoid arthritis patients several years later. Health care providers should assess pain and function and act on high pain and impaired function already at disease onset as they proved to be predictors of patient-reported outcomes controlled for inflammatory parameters. These findings support European guidelines and research findings that patients with high pain and impaired function despite of well-managed inflammatory parameters should early in the disease course be referred to multidisciplinary treatment for supplementary regime.

Entities:  

Keywords:  Functioning; pain; prognostic factors; rheumatoid arthritis

Mesh:

Year:  2014        PMID: 25036855     DOI: 10.3109/09638288.2014.939773

Source DB:  PubMed          Journal:  Disabil Rehabil        ISSN: 0963-8288            Impact factor:   3.033


  11 in total

1.  Coping and Life Satisfaction: Mediating Role of Ego-Resiliency in Patients with Rheumatoid Arthritis.

Authors:  Michał Ziarko; Ewa Mojs; Dorota Sikorska; Włodzimierz Samborski
Journal:  Med Princ Pract       Date:  2019-09-27       Impact factor: 1.927

2.  Response to methotrexate predicts long-term patient-related outcomes in rheumatoid arthritis.

Authors:  Dietmar Krause; Bernadette Gabriel; Gertraud Herborn; Juergen Braun; Rolf Rau
Journal:  Clin Rheumatol       Date:  2016-02-26       Impact factor: 2.980

3.  ADAR1 Prevents Liver Injury from Inflammation and Suppresses Interferon Production in Hepatocytes.

Authors:  Guoliang Wang; Hui Wang; Sucha Singh; Pei Zhou; Shengyong Yang; Yujuan Wang; Zhaowei Zhu; Jinxiang Zhang; Alex Chen; Timothy Billiar; Satdarshan P Monga; Qingde Wang
Journal:  Am J Pathol       Date:  2015-10-09       Impact factor: 4.307

4.  The influence of lifestyle habits on quality of life in patients with established rheumatoid arthritis-A constant balancing between ideality and reality.

Authors:  Karina Malm; Ann Bremander; Barbro Arvidsson; Maria L E Andersson; Stefan Bergman; Ingrid Larsson
Journal:  Int J Qual Stud Health Well-being       Date:  2016-05-10

5.  Rehabilitation for patients with rheumatic diseases: Patient experiences of a structured goal planning and tailored follow-up programme.

Authors:  Turid Nygaard Dager; Ingvild Kjeken; Gunnhild Berdal; Anne-Lene Sand-Svartrud; Ingvild Bø; Anne Dingsør; Siv Grødal Eppeland; Jon Hagfors; Bente Hamnes; Merete Nielsen; Bente Slungaard; Sigrid Hørven Wigers; Mona-Iren Hauge
Journal:  SAGE Open Med       Date:  2017-11-10

6.  The 8-foot up and go test is the best way to assess physical function in the rheumatoid arthritis clinic.

Authors:  Thomas J Wilkinson; Andrew B Lemmey; Rebecca J Clayton; Jeremy G Jones; Thomas D O'Brien
Journal:  Rheumatol Adv Pract       Date:  2017-12-08

7.  A Swedish register-based, long-term inception cohort study of patients with rheumatoid arthritis - results of clinical relevance.

Authors:  Ingiäld Hafström; Sofia Ajeganova; Maria LE Andersson; Sidona-Valentina Bala; Stefan Bergman; Ann Bremander; Kristina Forslind; Karina Malm; Björn Svensson
Journal:  Open Access Rheumatol       Date:  2019-09-09

8.  The Relation Between Disease Activity, Patient-Reported Outcomes, and Grip Force Over Time in Early Rheumatoid Arthritis.

Authors:  Maria Rydholm; Ingegerd Wikström; Sofia Hagel; Lennart T H Jacobsson; Carl Turesson
Journal:  ACR Open Rheumatol       Date:  2019-08-19

9.  Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM.

Authors:  Bruno Fautrel; Bruce Kirkham; Janet E Pope; Tsutomu Takeuchi; Carol Gaich; Amanda Quebe; Baojin Zhu; Inmaculada de la Torre; Francesco De Leonardis; Peter C Taylor
Journal:  J Clin Med       Date:  2019-09-05       Impact factor: 4.241

10.  A quality indicator set for rehabilitation services for people with rheumatic and musculoskeletal diseases demonstrates adequate responsiveness in a pre-post evaluation.

Authors:  Anne-Lene Sand-Svartrud; Gunnhild Berdal; Maryam Azimi; Ingvild Bø; Turid Nygaard Dager; Siv Grødal Eppeland; Guro Ohldieck Fredheim; Anne Sirnes Hagland; Åse Klokkeide; Anita Dyb Linge; Kjetil Tennebø; Helene Lindtvedt Valaas; Ann Margret Aasvold; Hanne Dagfinrud; Ingvild Kjeken
Journal:  BMC Health Serv Res       Date:  2021-02-20       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.